Sarepta’s External Controls Analysis Weakened By Elevidys Placebo Data Comparison

When placebo data from the only randomized trial of the Duchenne muscular dystrophy gene therapy were compared with Sarepta’s proffered external control data, the placebo subjects numerically outperformed the external controls, ‘calling into question the comparability of the external control group,’ an FDA statistical reviewer said.

Drug Review Profile: Elevidys
FDA reviewers did not see a case for Elevidys' efficacy in Sarepta's external controls comparison. • Source: Shutterstock

More from Drug Review Profiles

More from Product Reviews